M&A & Rare Disease
Italy’s Angelini Pharma to Buy U.S. Catalyst Pharma in $4.1 Billion Deal
By Intent.Health Team • May 7, 2026
What’s happening
Italy’s Angelini Pharma agreed to acquire U.S.-based Catalyst Pharmaceuticals in a deal valued at about $4.1 billion, expanding its presence in rare disease treatments.
What’s changing / Business impact
-
Expands international ownership of: U.S. pharmaceutical assets and rare disease portfolios.
-
Increases consolidation in specialty pharma.
-
Strengthens focus on: neurology and orphan drug markets.
Why this matters
Healthcare competition is increasingly global.
This shows:
-
Rare disease companies remain attractive acquisition targets.
-
Cross-border pharma consolidation continues accelerating.
-
Ownership shifts can reshape: pricing power, commercialization strategy, and market competition.